Evidence map›Paper›PMID 40563557›Full record

ArticleCancers2025

Laura De Marchis, Alain Jonathan Gelibter, Giulia Mammone, Raffaele Angelo Madaio, Paolo Aretini, Maria De Bonis, Stefania Zampatti, Cristina Peconi, Daniele Guadagnolo, Annarita Vestri and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Laura De MarchisDivision of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-2195-7955
Alain Jonathan GelibterMedical Oncology Unit B, Department of Hematology, Oncology and Dermatology, Policlinico Umberto I, 00161 Rome, Italy.
Giulia MammoneDivision of Medical and Translational Oncology, Azienda Ospedaliera Santa Maria, 05100 Terni, Italy.
Raffaele Angelo MadaioOncology Unit, Jewish Hospital of Rome, 00148 Rome, Italy.
Paolo AretiniFondazione Pisana per la Scienza, 56017 Pisa, Italy.ORCID 0000-0003-1075-4319
Maria De BonisDepartmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli IRCCS, 00168 Rome, Italy.
Stefania ZampattiGenomic Medicine Laboratory, UILDM IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0003-2502-7157
Cristina PeconiGenomic Medicine Laboratory, UILDM IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Daniele GuadagnoloDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0003-4588-1131
Annarita VestriDepartment of Public Health and Infectious Disease, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-6139-7174
Antonio PizzutiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Emiliano GiardinaDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
Ettore Domenico CapoluongoDipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, 80146 Naples, Italy.
Angelo MinucciGenomic Medicine Laboratory, UILDM IRCCS Santa Lucia Foundation, 00179 Rome, Italy.ORCID 0000-0002-0833-4334

Funding

sapienza PI116154FE2020D0
6 · The paper itself

Abstract

BACKGROUND/

objectivesCancer risk-reducing strategies in Ashkenazi women carrying founder variants have a cost-effective effect on reducing cancer morbidity and mortality. The British and US guidelines recommend

methodsPatients were selected from the Family Cancer Clinic of the Umberto I University Hospital of Rome, and 38 unrelated families (28 of Roman Jewish and 10 of Libyan Jewish origin) were enrolled, comprising 44 subjects diagnosed with breast and/or ovarian cancer. Genetic counseling and germline

resultsOf the probands, 26.5% (9/34) from 7/28 unrelated families (25%) in the Jewish community of Rome harbored the known

conclusionsThis study indicates the

Indexed as

BRCA1/2 genesc.7007G>C variantethnical minoritiesfounder mutationhaplotypeJewish communities

Identifiers

PMID40563557
PMCPMC12190740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.